{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:24:05Z","timestamp":1771885445213,"version":"3.50.1"},"update-to":[{"DOI":"10.1080\/13696998.2022.2082200","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000}}],"reference-count":17,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2197812","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T17:54:40Z","timestamp":1680544480000},"page":"627-629","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Re: The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United States"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6497-7387","authenticated-orcid":false,"given":"Camille","family":"Rochmann","sequence":"first","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-1706","authenticated-orcid":false,"given":"Marie","family":"Fournier","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2799-7391","authenticated-orcid":false,"given":"Judy","family":"Hull","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9803-6385","authenticated-orcid":false,"given":"Maria","family":"Perichon","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0630-960X","authenticated-orcid":false,"given":"Ruth","family":"Pulikottil-Jacob","sequence":"additional","affiliation":[{"name":"Sanofi, Reading, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2082200"},{"key":"e_1_3_4_3_1","unstructured":"CEREZYME [Prescribing information] 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020367_S119lbl.pdf"},{"key":"e_1_3_4_4_1","unstructured":"VPRIV [Prescribing information] 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022575lbl.pdf"},{"key":"e_1_3_4_5_1","unstructured":"ELELYSO [Prescribing information] 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022458lbl.pdf"},{"key":"e_1_3_4_6_1","unstructured":"CERDELGA [Prescribing information]. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205494orig1s000lbl.pdf"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.09.002"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26276"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2014.04.002"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25300"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758409"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25875"},{"issue":"1","key":"e_1_3_4_13_1","first-page":"1","article-title":"Four-year real-world effectiveness of eliglustat in treatment-na\u00efve and switch patients enrolled in the international collaborative gaucher group (ICGG) gaucher registry","volume":"45","author":"Mistry PB","year":"2022","unstructured":"Mistry PB, Sekulic D. Four-year real-world effectiveness of eliglustat in treatment-na\u00efve and switch patients enrolled in the international collaborative gaucher group (ICGG) gaucher registry. J Inherited Metab Dis. 2022;45(S1):1\u2013870.","journal-title":"J Inherited Metab Dis"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.07.011"},{"key":"e_1_3_4_15_1","unstructured":"Zavesca (Miglustat). Gaucher Disease News [cited 2022 Oct 12]. https:\/\/gaucherdiseasenews.com\/zavesca-miglustat\/"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.10.1002"},{"key":"e_1_3_4_17_1","unstructured":"CERDELGA \u00ae (eliglustat) capsules for oral use. 2022. https:\/\/www.sanofi.us\/dam\/jcr:75688713-1a55-41d7-a05c-509257a8f26c\/Cerdelga_Sanofi_US_CO_Form_11521.pdf"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","unstructured":"Mistry PBJ Sekulic D editor. Four-year real-world effectiveness of eliglustat in treatment-na\u00efve and switch patients enrolled in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Society for the Study of Inborn Errors of Metabolism 2022.","DOI":"10.1097\/01.HS9.0000973228.21913.33"}],"updated-by":[{"DOI":"10.1080\/13696998.2023.2197785","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000}}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2197812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:03:21Z","timestamp":1701943401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2197812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2197812"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2197812","relation":{"addendum":[{"id-type":"doi","id":"10.1080\/13696998.2023.2197785","asserted-by":"object"}]},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}